The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Related News Articles

Perspective
Public
Congress returns to Washington, D.C., this week facing a long list of things to do, including several that will impact hospitals’ ability to provide access to…
Headline
The AHA Sept. 4 expressed support for the Hospitals As Naloxone Distribution Sites Act (H.R. 5120), legislation that would require Medicare and Medicaid to…
Headline
The House Appropriations Committee today released the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services, Education,…
Headline
The AHA Aug. 11 urged the Centers for Medicare & Medicaid Services to prioritize payments to hospitals from the Rural Health Transformation Program. The…
Headline
The AHA and Federation of American Hospitals Aug. 8 filed an amicus brief in the U.S. District Court for the Eastern District of Texas in support of the U.S.…
Headline
President Trump Aug. 7 issued an executive order, “Improving Oversight of Federal Grantmaking,” requiring government agencies to review new and discretionary…